Re: Planning EP diary for 2017 What about any cash shortfall prior to cash flow positive, abridge is probably needed for a couple more quarters?
Re: Planning EP diary for 2017 "What alternative...."Make a profit? Hopefully in US in next 6/12 and company wide as soon as NHS has to order.Regards, Seadoc
Re: Planning EP diary for 2017 What alternative beyond a trade sale or merger?
Planning EP diary for 2017 I have it in mind, to expect next cash-call by Dec 2017, meaning a further share issue with dilution for existingDo others share same view?
Re: RNS Share Options I suggest what really matters to EP & his board is that investors continue to be willing to fund more cash-callsAnd, so far at least, EP has been successful in achieving that
Zeus Capital published a note out this morning on Research Tree: "Deltex Medical Group plc (DEMG), the global leader in the field of Oesophageal Doppler Monitoring (ODM), today announced the establishment of two new platform programme accounts in the USA. Deltex has now established 7 new hospital accounts in the US this year and with 24 in total is well on the way to achieving its target of 30 in Q3 2016. One of the new accounts is with a large hospital in the San Francisco area within Deltex’s West Coast sales territory which is contracted to minimum order volumes of 30 probes per month following the initial order of 50 probes."
Zeus Capital's note out this morning on Research Tree: "Deltex Medical Group plc (DEMG), the global leader in the field of Oesophageal Doppler Monitoring (ODM), today announced excellent initial results from the largest ever randomised clinical trial (conducted in 450 patients undergoing major surgery in 5 hospitals in Spain) assessing the impact of oesophageal Doppler monitoring (ODM) on post-operative complications. As a result of these findings, presented at the Euroanaesthesia 2016 conference in London, ODM is indicated as the preferred method for intra-operative fluid manage..."